Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1

Interventions

Psychiatric Rehabilitation 4sargramostim 2Early Intervention, Educational 2Drug Therapy 2neratinib 1ixabepilone 1carboxyamido-triazole 1Topotecan 1Thiotepa 1Thalidomide 1Temozolomide 1Surveys and Questionnaires 1Specimen Handling 1Rituximab 1Respiratory Function Tests 1Radiotherapy 1Quality of Life 1Positron-Emission Tomography 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1Oxycodone 1O(6)-benzylguanine 1Nivolumab 1N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 1Morphine 1Molecular Diagnostic Techniques 1Methotrexate 1Methadone 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × Fenofibrate × Other hematologic neoplasm × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡